These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8518223)

  • 1. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Ann Oncol; 1993 Apr; 4(4):317-20. PubMed ID: 8518223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
    van Groeningen CJ; Peters GJ; Leyva A; Laurensse E; Pinedo HM
    J Natl Cancer Inst; 1989 Jan; 81(2):157-62. PubMed ID: 2909757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
    Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
    Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of fluorouracil toxicity with uridine.
    van Groeningen CJ; Peters GJ; Pinedo HM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):148-54. PubMed ID: 1557641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
    Kelsen DP; Martin D; O'Neil J; Schwartz G; Saltz L; Sung MT; von Borstel R; Bertino J
    J Clin Oncol; 1997 Apr; 15(4):1511-7. PubMed ID: 9193347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
    Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
    Saif MW; Diasio RB
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
    Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Fernández-Martos C; Antón-Torres A; Massutí T; Barneto I; García-Conde J; Barón JM; Díaz-Rubio E
    Ann Oncol; 1996 Aug; 7(6):581-5. PubMed ID: 8879371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
    Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
    Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
    Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
    van Groeningen CJ; Leyva A; Kraal I; Peters GJ; Pinedo HM
    Cancer Treat Rep; 1986 Jun; 70(6):745-50. PubMed ID: 3731137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
    Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
    Hejna M; Kornek GV; Raderer M; Valencak J; Weinländer G; Fiebiger W; Miholic J; Scheithauer W
    Ann Oncol; 1998 Dec; 9(12):1309-14. PubMed ID: 9932161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
    Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.